"I've had quite a few people contact me, but I'll place RBW right amongst the top. Highly professional, very personable, approachable and most importantly delivers results. Would highly recommend their services."

BLOG: Biologics and Gene Therapy - CDMO Trends
14th June 2019

Written by Tamsynne Searle

website_blog_597

 

Trends show that outsourcing to Contract Development and Manufacturing Organisations (CDMOs) has been on the rise in the last decade or so and this has been driven by several factors. I wanted to explore the current trends and factors within the CDMO market and what this means for commercial recruitment within the CDMOs.

 

Growing Marketplace

In the UK, there are approximately 360,000 new cases of cancer reported each year. That’s a staggering 990 new cancer cases each day. This is reflected in the current value of the Global Oncology Market which equates to $77.3B; but what does this mean for the CDMO market? As the need for the targeted therapeutics increases year on year, the need for commercial-scale manufacturing of biopharmaceuticals grows stronger and stronger.

 

Complexity

These “designer” therapeutics add a layer of complexity to the drug development and manufacturing process, as the more targeted the drug, the more complex the molecule is to handle. The mainstream approach of molecules that are simple to manufacture has gone out the window and the need for expertise is on the rise. Big pharma, and smaller biotechs alike, rely on the expertise CDMOs can offer, allowing these complex drug products to make it to market.

 

Cost

One of the biggest concerns of pharmaceutical and biotechnology companies is the financial cost in the development and manufacturing of these breakthrough therapeutics. Whether you are a large pharma looking to cut costs by outsourcing this expensive part of the process, or a smaller biotech that simply cannot afford to invest in manufacturing capabilities, CDMOs offer the capabilities and expertise to handle the products’ journey from development through to commercialisation.

As we make a move away from blockbusters towards personalised therapeutics, we see the clear rise in demand for reliable, efficient and tailored CDMOs. Currently the top five CDMOs collectively account for just 15% of the market with 100 smaller manufacturers also offering similar services.

 

What are the corresponding implications for commercial recruitment within the biologics and gene therapy CDMO space?

As a result of my networking within the industry, I speak to commercial and operational CDMO professionals on a daily basis.  They all feel that as the demand for personalised therapeutics rises, so will the need for more CDMOs who have the capabilities and expertise to deal with the development and manufacturing of these complex solutions. CDMOs are searching for Business Developers to go out to these key industry leaders to offer a service which can be tailored to their individual and very specific needs. Employees are finding technical understanding a key point when hiring Business Developers as each and every customer needs a tailored experience which calls for expert solutions.

The importance of recruiting the right staff within the commercial biologics CDMO space is what really motivates my recruitment work, as I can see the clear difference that these individuals make to my clients’ business, to the pharma and biotech industries, and so ultimately to patients. This market has started to grow with CDMOs investing in new biologics manufacturing sites and with more capacity to bring on new projects, the need for Business Developers to actively go out and win new business is on the rise. Now more than ever, CDMOs are investing time and money into finding top talent within the biologics field.

 

I am currently working with a number of such biologics and gene therapy CDMOs in the US and Europe who are searching for top class salespeople who have a strong technical understanding of the service on offer so they can offer their customers the “designer” experience they need. Let’s connect and discuss these market trends and current opportunities in more detail.

 

Written by Tamsynne Searle

tamsynne.searle@rbwconsulting.com | +44 (0)1293 584 300

 

Return to news menu

 



This website may use cookies to provide an improved experience. You can refuse these cookies by changing your browser settings.
To remove this message, click here to accept cookies.